Moreover, elevated levels of EVs containing a cell surface proteoglycan, glypican-1 (GPC1) have emerged as a potential biomarker, showing markedly higher concentrations in patients with PDAC [437] and CRC [438] than in healthy individuals. This evidence concerns the gene GPC1 and colorectal carcinoma.